Stock analysts at StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Get Free Report) in a research note issued on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Agile Therapeutics Price Performance
Shares of NASDAQ AGRX opened at $1.51 on Thursday. Agile Therapeutics has a 52-week low of $0.20 and a 52-week high of $2.63. The firm has a fifty day moving average of $1.48 and a 200-day moving average of $0.88. The stock has a market capitalization of $10.35 million, a PE ratio of -0.41 and a beta of 1.58.
Agile Therapeutics (NASDAQ:AGRX – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter. The company had revenue of $5.58 million for the quarter.
Institutional Trading of Agile Therapeutics
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
See Also
- Five stocks we like better than Agile Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Upcoming IPO Stock Lockup Period, Explained
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.